期刊文献+

利妥昔单抗对急性白血病患者树突细胞功能的影响 被引量:1

Effects of rituximab on dendritic cell function of patients with acute leukemia
下载PDF
导出
摘要 目的探讨利妥昔单抗治疗急性白血病过程中,对树突细胞功能的影响。方法随机选取我院采取利妥昔单抗治疗的急性白血病(AL)患者100例,取治疗有效患者和正常人的外周血单个核细胞(PBMC)进行体外培养,获得成熟的树突细胞(DC)后进行实验学检测,包括倒置显微镜、流式细胞术和MTT法等,对两组细胞的各项检测结果进行比较,判定利妥昔单抗治疗对DC功能的影响。结果利妥昔单抗治疗后诱导的DC体积较小,细胞核居中,形态规则;细胞培养3 d后进入指数生长期,6~7 d后进入平台期,增殖能力弱;治疗后DC诱导淋巴细胞增殖指数较治疗前明显减低。利妥昔单抗治疗后,DC的CD80、CD83和CD86的阳性表达率明显低于治疗前,治疗后的DC和正常DC各项检查结果间有统计学差异(P<0.05)。结论利妥昔单抗对于急性白血病有一定的治疗作用,治疗后的DC增殖缓慢,且对于淋巴细胞的刺激作用减弱,淋巴细胞的增殖指数降低。 Objective To discuss treatment of acute leukemia by rituximab and its effect on the function of dendritic cells. Methods 100 patients with acute leukemia(AL) and receiving the treatment with rituximab were randomly selected. Peripheral blood mononuclear cells (PBMC)of the patients with effective treatment and the healthy people were obtained and cultured in vitro. After the mature dendritic cells (DC)were successfully obtained, various experimental studies were carried out for the detection, such as inverted microscopy, flow cytometry, and MTT method, etc. Comparison was made between the detection results of the two groups. And the effects of rituximab on the function of dendritic cell were determined. Results After the treatment by rituximab, induced dendritic cell volume was smaller with the nucleus in the center and regular morphous. After the culture for 3 days, the cells entered the exponential growth phase and 6 to 7 days later the platform phase, and the proliferative capacity was weak. After the treatment, the proliferation index of DC induced lymphocyte significantly decreased. After the treatment by rituximab, the positive expression rates of CD80, CD83 and CD86 was significantly lower than those before the treatment, and there were significant differences between examination resuhs of the patients'and healthy people's DC ( P 〈 0.05 ). Conclusion Rituximab has certain curative effect on acute leukemia. After the treatment, the proliferation of DC is slow;the lymphocyte stimulation is weakened;the lymphocyte proliferation index decreases.
出处 《西南国防医药》 CAS 2013年第4期363-365,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 利妥昔单抗 急性白血病 树突细胞 功能 rituximab acute leukemia dendritic cells function
  • 相关文献

参考文献10

二级参考文献50

  • 1高霞,张连生,柴晔,张玉芳,易良才,宋飞雪,刘瑛,曾鹏云,赵丽,唐文茹.Flt3配体诱导急性淋巴细胞白血病来源树突细胞及其功能的研究[J].中华血液学杂志,2004,25(11):691-694. 被引量:3
  • 2邹农,华宝来,王书杰,朱铁楠,赵永强.利妥昔单抗治疗难治性特发性血小板减少性紫癜一例[J].中华医学杂志,2005,85(6):432-432. 被引量:4
  • 3周泽平,杨仁池.B细胞清除治疗(美罗华)在ITP中的临床应用进展[J].国际输血及血液学杂志,2006,29(6):495-498. 被引量:9
  • 4李沛寰,陈辉树.树突状细胞与自身免疫性疾病关系的研究进展[J].医学综述,2007,13(6):411-413. 被引量:7
  • 5中华医学会血液学学会血栓与止血学组.几种出血性疾病诊断(及疗效)标准的修订[J].中华血液学杂志,1995,16:331-331. 被引量:81
  • 6Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20 Hodgkin's lymphoma with the monocleonal antibody rituximab is effective and well tolerated:result of a phase 2 trail of the German Hodgkin's lymphoma study Group[J]. Blood, 2003,101 (2) : 420. 被引量:1
  • 7Hoehster HS,Weller E,Ryan T,et al. Results of E1496:a phase Ⅲ trial of CVP with or without maintenance rituximab in advanced indolent lymphoma(NHL) [J]. Proc Am Soc Clin Oncol,2004,22(14) :6502. 被引量:1
  • 8Pfreundsehuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP- like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interimanalysis[J]. Proc Am Soc Clin Oncol, 2004,22 (14): 6500. 被引量:1
  • 9Hiddemann W, Dreyling M, Unterhalt M, et al. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and time to treatment failure(TTF) compared to CHOP alone in mantle cell lymphoma(MCL): resuhs of a prospective randomizedtrial of the German Low Grade Lymphoma Study Group(C-LSG) [J]. Proc Am Soc Clin Oncol, 2004, 22 (14) :6501. 被引量:1
  • 10Zent CS, Secreto CR, Implant BR, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early intermediate stage chronic lymphocytic leukemia(CLL) treated with alemtuzumab and rituximab[J]. Leuk Res, 2008,32 (12) : 1849. 被引量:1

共引文献278

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部